- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.01. | ST Pharm inks $56M deal to produce API for a US biotech | ||
| 23.01. | Lilly battles weight stigma in short film centering obesity conversation on health, not appearance | ||
| 23.01. | RFK Jr.'s new ACIP chair stresses 'individual autonomy,' questions polio shot guidance on podcast | ||
| 23.01. | Novo's Wegovy pill launch wows with strong early uptake: analysts | ||
| 23.01. | Bausch Health's $2B pursuit of Xifaxan successor hits wall with phase 3 failure | ||
| 23.01. | Ocular drafts Eylea launch architect to lead attack on Regeneron's blockbuster | ||
| 22.01. | Global pharma manufacturing output surged in '25 in 'front-loading' response to US tariff threats: report | ||
| 22.01. | Invivyd teams up with Olympic skier Lindsey Vonn for antibody education | ||
| 22.01. | CEPI bankrolls $30M Ebola vaccine collaboration with Merck, SK Biosciences and others | ||
| 22.01. | Lundbeck 'not willing to compromise' on M&A strategy after missed Avadel attempt: exec | ||
| 22.01. | Trump's Davos drug pricing claims decried as 'fake news' by French presidency | ||
| 22.01. | Samsung Bio sticks landing on 2025 as it becomes first Korean biopharma to hit 2T won profit threshold | ||
| 21.01. | In J&J talc litigation, N.J. court-appointed official recommends allowing expert testimony | ||
| 21.01. | Led by Darzalex surge, J&J expects revenue to reach $100B in 2026 | ||
| 21.01. | IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win | ||
| 21.01. | Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ | ||
| 20.01. | GSK licenses Alteogen enzyme in bid to develop subQ Jemperli | ||
| 20.01. | Takeda's neuroscience field force hit with layoffs as key patent loss looms for Trintellix | ||
| 20.01. | Definium defines mental health applications for LSD in new awareness campaign | ||
| 20.01. | Supreme Court agrees to review 'skinny label' battle between Hikma, Amarin over generic Vascepa | ||
| 20.01. | Roche scales Genentech's North Carolina site to $2B in major obesity market play | ||
| 20.01. | Valneva withdraws chikungunya vaccine Ixchiq from US amid new FDA investigation | ||
| 20.01. | Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company | ||
| 20.01. | Trump's new tariff threats around Greenland risk upending EU trade deal | ||
| 20.01. | Apiject signs lease for new generics blow-fill-seal manufacturing facility in N.C. |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.